Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blinded, Randomized, Placebo-controlled, Dose-Exploring Study of RX-10100 When Given for Eight Consecutive Weeks to Subjects With Major Depression Disorder (MDD)

NCT00839176 is registered in ClinicalTrials.gov with Rexahn Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00839176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00839176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blinded, Randomized, Placebo-controlled, Dose-Exploring Study of RX-10100 When Given for Eight Consecutive Weeks to Subjects With Major Depression Disorder (MDD)
Lead sponsor
Rexahn Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
October 31, 2009
Enrollment
118 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)